ImmunityBio, Inc.
ImmunityBio Reports Significant Growth in Q1 2025 Revenue and ANKTIVA Sales
Summary
ImmunityBio, Inc. reported substantial growth in Q1 2025, achieving a 129% increase in net product revenue to $16.5 million, driven by the successful launch of ANKTIVA and the impact of the permanent J-code (J9028) approved in January 2025. Unit sales volume for ANKTIVA also grew by 150% compared to the previous quarter, with positive long-term results from the QUILT 3.032 study, and the company completed a $75 million equity financing to support ongoing operations.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement